Catalyst Pharmaceuticals (CPRX) Raw Materials (2023 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Raw Materials came in at $16.9 million in Q1 2026, up 127.02% YoY from $7.4 million in Q1 2025, and down 1.51% on a QoQ basis from $17.1 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Raw Materials (2023 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 4 years of Raw Materials data on file, last reported at $16.9 million in Q1 2026.
- Quarterly Raw Materials rose 127.02% year-over-year to $16.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.9 million (up 127.02% YoY) and the FY2025 annual result came in at $17.1 million, up 162.92% from the prior year.
- Raw Materials fell to $16.9 million in Q1 2026, from $17.1 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $17.1 million in Q4 2025 to a low of $1.9 million in Q4 2023.
- A 4-year average of $8.9 million and a median of $6.9 million in 2024 frame the typical range for Raw Materials.
- Annual changes were most pronounced in 2024 — Raw Materials surged 241.26% — and 2025, when it declined 7.34%.
- Tracing CPRX's Raw Materials over 4 years: stood at $1.9 million in 2023, then surged by 241.26% to $6.5 million in 2024, then jumped by 162.92% to $17.1 million in 2025, then declined by 1.51% to $16.9 million in 2026.
- The last three Raw Materials figures came in at $16.9 million (Q1 2026), $17.1 million (Q4 2025), and $12.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.88 Mn |
| Dec 31, 2025 | 17.14 Mn |
| Sep 30, 2025 | 12.14 Mn |
| Jun 30, 2025 | 5.19 Mn |
| Mar 31, 2025 | 7.44 Mn |
| Dec 31, 2024 | 6.52 Mn |
| Sep 30, 2024 | 6.95 Mn |
| Jun 30, 2024 | 5.60 Mn |
| Dec 31, 2023 | 1.91 Mn |